

I hereby certify that this correspondence is being transmitted via the Office electronic filing system to the United States Patent and Trademark Office, on the date shown below.

Dated: April 3, 2008

Signature: /Mark D. Russett/  
Mark D. Russett, Reg. No. 41, 281

Docket No.: 66043(70820)  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Shogo Marui et al.

Application No.: 10/591,561

Confirmation No.: 3122

Filed: August 31, 2006

Art Unit: 1625

For: COUMARIN DERIVATIVE AND USE  
THEREOF

Examiner: N.S. Chandrakumar

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.56, 1.97, and 1.98, Applicant(s) hereby make of record the following documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Applicants are aware of certain documents, cited in an "International Search Report" (ISA) and "International Preliminary Report on Patentability" (IPRP) in PCT patent application no. PCT/JP2005/003838, of which the present application is the U.S. national phase application. In accordance with 37 CFR 1.97, Applicants hereby submit these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the ISA and IPRP and each document required under 37 CFR 1.98(a)(2) cited thereon is enclosed as well, except that Applicants note that two citations (WO 03/059900 and EP-A-1 302 470) of the ISA and IPRP have already been made of record in the present application with the Information

Disclosure Statement of August 31, 2006 (as citations BA and BB therein), so no copies are enclosed herewith. In addition, citations AB-AD on the enclosed PTO Form SB/08 represent corresponding U.S. patents/applications of EP-A-1 302 470 and JP2002-255808, and citation AE represents a corresponding U.S. application of WO 03/059900, cited in the ISA and IPRP. In accordance with 37 CFR 1.98(a)(2)(ii), Applicants have not submitted copies of U.S. patents and U.S. patent applications.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 66043(70820).

Dated: April 3, 2008

Respectfully submitted,

By           /Mark D. Russett/            
Mark D. Russett, Registration No.: 41,281  
EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 239-0100  
Attorneys/Agents For Applicants